Cerecor

About

Avalo is a clinical-stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases. Avalo is advancing its lead anti-IL-1β monoclonal antibody (mAb) drug candidate, abdakibart, into a phase 3 registrational program in hidradenitis suppurativa (HS). We are pursuing additional development opportunities in IL-1β driven indications. Avalo is also developing AVTX-010, […]